Valneva SE
corporate_fare Company Profile
Valneva SE (NASDAQ:VALN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for VALN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for VALN spans 6-K, 424B3, F-3, SCHEDULE 13D/A.
Recent high-impact activity:
- Valneva 6-K Packs Shigella Phase 2 Win and 94% Five-Year Chikungunya Persistence
- Valneva's Shigella Vaccine Hits Phase 2 Endpoints in Infant and Adult Trials
- UK Revokes Marketing Authorization for Valneva's Chikungunya Vaccine
- EMA Validates Valneva's Lyme Vaccine MAA; Phase 3 Shows >70% Efficacy
- Valneva H1 2026: Net Loss Triples to €63.3M on IXCHIQ Charges; Guidance Reaffirmed
Financial Snapshot
Short Interest & Short Volume
2.05 days to coverFINRA reported short interest of 47,986 shares in VALN as of the October 30, 2026 settlement, a 75.0% decrease from the prior period — about 2.0 days to cover at its recent average daily volume. On November 19, 2026, 15.7% of VALN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for VALN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-04.
Resale Registration Filed · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
VALN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.